

**UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF CALIFORNIA**

IN RE IMMUNITYBIO, INC. SECURITIES  
LITIGATION

No. 3:23-cv-01216-GPC-VET

THIS DOCUMENT RELATES TO:  
ALL ACTIONS

**NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION, MOTION FOR  
ATTORNEYS' FEES AND EXPENSES, AND SETTLEMENT FAIRNESS HEARING**

If you purchased or acquired ImmunityBio, Inc. ("ImmunityBio") (NASDAQ: IBRX) securities between March 10, 2021, and May 10, 2023, both dates inclusive (the "Settlement Class Period"), you could be entitled to a payment from a proposed class action settlement.

*A federal court authorized this Notice. It is not a solicitation from a lawyer.*

- A proposed settlement (the "Settlement") has been reached in the above-captioned class action (the "Action") on behalf of all persons who purchased or acquired ImmunityBio securities during the Settlement Class Period and were damaged thereby (the "Settlement Class," and each member thereof, a "Settlement Class member"). The terms of the Settlement are set forth in a Stipulation of Settlement, dated January 28, 2025 (the "Stipulation").
- The United States District Court for the Southern District of California (the "Court") will hold a hearing (the "Settlement Fairness Hearing") on June 13, 2025 to decide whether to approve the Settlement. If approved by the Court, the Settlement will provide a gross amount of ten million five hundred thousand dollars (\$10,500,000.00) (the "Settlement Amount"), plus interest earned thereon, minus attorneys' fees, costs, administrative expenses, and any compensatory award to Court-appointed lead plaintiff Dipak Patel ("Lead Plaintiff"), and net of any taxes, to pay claims of Settlement Class members.
- The Settlement represents an average recovery of \$0.14 per share of ImmunityBio stock for the 75.41 million estimated shares that Lead Plaintiff alleges declined in value as a result of Defendants' alleged misconduct during the Settlement Class Period. This estimate solely reflects the average recovery per damaged share of ImmunityBio stock before the deductions outlined in the previous bullet-pointed paragraph of this section. This is not an estimate of the actual recovery per share you should expect. Your actual recovery will be affected by the aggregate losses of all Settlement Class members, the date(s) you purchased and/or sold ImmunityBio securities, and the total number of valid claims filed. See the "Plan of Allocation of Net Settlement Fund Among Settlement Class Members" section at the end of this Notice for more details.
- To claim your share of the Settlement, you must submit a valid Proof of Claim and Release Form (a "Proof of Claim") by July 7, 2025.
- Co-Lead Counsel for the Settlement Class intends to ask the Court to award them fees in an amount not to exceed one third (33 and 1/3%) of the Settlement Amount and reimbursement of up to two hundred thousand dollars (\$200,000) in out-of-pocket litigation expenses, plus interest earned on such fees and expenses. Since the Action's inception in June 2023, Co-Lead Counsel have expended considerable time and effort in the prosecution of this litigation on a wholly contingent-fee basis (meaning that they have not yet been paid anything) and advanced the expenses of the litigation out of their own pockets in the expectation that, if they were successful in obtaining a recovery for the Class, they would be paid from such recovery. Co-Lead Counsel also intends to ask the Court to grant Lead Plaintiff an award in an amount not to exceed fifteen thousand dollars (\$15,000.00). Collectively, the attorneys' fees and litigation expenses and the award to Lead Plaintiff are estimated to average an amount not to exceed \$0.05 per damaged share of ImmunityBio stock. The average cost per damaged share will vary depending on the number of acceptable Proofs of Claim submitted. If approved by the Court, these amounts will be paid from the Settlement Fund.
- The approximate recovery, after the deduction of attorneys' fees and expenses and award to Lead Plaintiff to be approved by the Court, is an average of at least \$0.09 per damaged share of ImmunityBio stock. This estimate is based on the assumptions set forth in the preceding paragraph. Your actual recovery, if any, will vary depending on the purchase price and/or sales price for each relevant transaction and the number of valid Proofs of Claim filed.

## EXHIBIT B-1

- The Claim Administration fees are not expected to exceed \$350,000. If the entire amount budgeted for administrative expenses were incurred, funds available for distribution would be reduced by approximately 3.3%.
- The Defendants are ImmunityBio and the Individual Defendants Richard Adcock (“Adcock”), David C. Sachs (“Sachs”), and Patrick Soon-Shiong (“Soon-Shiong”). Lead Plaintiff and Defendants are collectively referred to as the “Parties.”
- Upon the Effective Date of the Settlement, any and all of Lead Plaintiff’s Claims will be fully and unconditionally released as to Defendants and all of the other Released Defendant Parties. Upon the Effective Date, and as a material condition of the dismissal with prejudice of the Action, any and all of Defendants’ Claims will be fully and unconditionally released as against Lead Plaintiff and the other Released Lead Plaintiff Parties, including Co-Lead Counsel and all Settlement Class members.
- The Settlement resolves claims asserted in the Action concerning whether Defendants violated U.S. federal securities laws by allegedly issuing materially false and misleading statements. Defendants and Lead Plaintiff disagree on liability and damages. Defendants deny the lawsuit’s allegations and all charges of wrongdoing, fault, or liability against them arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Action. Defendants deny that Lead Plaintiff and other Settlement Class members suffered any damages attributable to Defendants’ alleged wrongdoing. Lead Plaintiff believes that his claims have merit and that, if he prevailed on all his claims and the Court accepted his theory of damages, he would have been able to collect a substantial amount of money, assuming that the full amount of the judgment was collectable. The Parties disagree on how much money could have been won if Lead Plaintiff won at trial.
- Your legal rights will be affected whether you act or do not act. If you do not act, you may permanently forfeit your right to recover on any claim you might have. Therefore, you should read this notice carefully.

<b>YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT</b>	
<b>SUBMIT A CLAIM FORM</b>	The only way to get a payment. Proof of Claim and Release Forms must be received no later than <b>July 7, 2025</b> .
<b>EXCLUDE YOURSELF</b>	Get no payment. This is the only option that allows you to ever be part of any other lawsuit against the Defendants or any other Released Parties about the legal claims in this Action. Requests for exclusion must be received no later than <b>May 23, 2025</b> .
<b>OBJECT</b>	Write to the Court about why you do not like the Settlement, the Plan of Allocation, and/or the request for attorneys’ fees, costs, and expenses or the compensatory award to Lead Plaintiff. You still will be a member of the Settlement Class. Objections must be received by the Court, Co-Lead Counsel, and Defendants’ counsel by <b>May 23, 2025</b> .
<b>GO TO THE HEARING</b>	Ask to speak in Court about the fairness of the Settlement on <b>June 13, 2025</b> .
<b>DO NOTHING</b>	Get no payment. Give up your rights.

### INQUIRIES

For further information regarding the Action or this Notice or to review the Stipulation, please contact the Claims Administrator toll-free at 1-888-853-4782 or visit the Settlement website at [www.ImmunityBioSecuritiesSettlement.com](http://www.ImmunityBioSecuritiesSettlement.com). You may also contact representatives of Co-Lead Counsel for the Settlement Class by contacting Jeremy Lieberman, Pomerantz LLP, 600 Third Ave., 20th Floor, New York, NY 10016, (212) 661-1100 and/or Corey D. Holzer, Holzer & Holzer, LLC, 211 Perimeter Center Parkway, Suite 1010, Atlanta, GA 30346, (770) 392-0090. **Please do not contact the Court, the Clerk of the Court, or Defendants regarding this Notice.**

## BASIC INFORMATION

### 1. Why did I get this notice package?

You or someone in your family may have purchased or acquired ImmunityBio (NASDAQ: IBRX) securities during the Settlement Class Period of March 10, 2021, and May 10, 2023, both dates inclusive.

The Court directed that this Notice be sent to Settlement Class members because they have a right to know about the proposed Settlement of this class action lawsuit and about all of their options before the Court decides whether to approve the Settlement. If the Court approves the Settlement and after objections and appeals—if any—are resolved, the Claims Administrator appointed by the Court will make the payments provided for in the Settlement.

### 2. What is this lawsuit about?

The Action is known as *In re ImmunityBio, Inc. Securities Litigation*, Case No. 3:23-cv-01216-GPC-VET and is pending in the United States District Court for the Southern District of California. The Action has been overseen by the Honorable Gonzalo P. Curiel, United States District Court Judge.

This Action brings claims against Defendants for alleged violations of provisions of the Securities Exchange Act of 1934 (the “Exchange Act”). The First Amended Class Action Complaint (“FAC”) alleges, among other things, that Defendants made misrepresentations and/or omissions of material fact in public statements regarding ImmunityBio’s manufacturing capabilities, compliance with required current good manufacturing practices (“cGMP”) promulgated by the U.S. Food and Drug Administration (“FDA”), and the FDA approval prospects for its lead product candidate, Anktiva. It further alleges that communications with the contract manufacturing organizations (each, a “CMO”) that manufactured Anktiva for ImmunityBio, documentation received from the FDA, and mock inspections of a CMO alerted the Company to cGMP violations and the risk of non-approval or delay of the Biologics License Application it submitted to the FDA for Anktiva, yet Defendants did not adequately disclose this information. The FAC alleges that, among other things, this conduct was not known to investors until the FDA released a Complete Response Letter on May 11, 2023. The FAC further alleges that the revelation of Defendants’ alleged fraud caused a statistically significant stock price decline, thereby injuring Lead Plaintiff and other Settlement Class members. Defendants have consistently denied, and continue to deny, each and every one of these allegations and deny they have committed any act or omission giving rise to any liability or violation of the law.

### 3. Why is this a class action?

Classes are generally used in lawsuits that affect a large number of individuals. A class action consolidates into a single action all of the claims of individuals allegedly harmed by the same conduct or course of conduct in the same period of time, thus removing the need for members of the class to file their own individual lawsuits to seek recovery for the harm alleged. Once the class is certified, the Court is empowered to resolve all issues on behalf of members of the class, except for those class members, if any, who specifically choose to exclude themselves from the class.

As part of the Settlement approval process, Lead Plaintiff will ask the Court to certify a class for settlement purposes only. The proposed Settlement Class will consist of all persons who purchased or acquired ImmunityBio (NASDAQ: IBRX) securities between March 10, 2021, and May 10, 2023, both dates inclusive, except those expressly excluded. Excluded from the Settlement Class are Defendants; members of the immediate family of the Defendants; the subsidiaries and affiliates of any Defendants; any entity in which any Defendant had a controlling interest during the Settlement Class Period; any person or entity who is a partner, executive officer, director or controlling person of any of the Defendants; any entity in which any Defendant has a controlling interest; and the legal representatives, heirs, successors and assigns of any such excluded party. Also excluded from the Settlement Class are any Settlement Class members who or which submit a valid request for exclusion from the Settlement Class in accordance with the requirements established by the Court, outlined below.

### 4. Why is there a settlement?

This Action has not gone to trial, and the Court has not decided in favor of either side. Instead, legal counsel for all the parties participated in an all-day mediation before an experienced, neutral mediator and, after further negotiations, the Parties agreed to, and memorialized, the Settlement to avoid the costs and risks of further litigation.

## EXHIBIT B-1

Lead Plaintiff and Co-Lead Counsel believe that the Settlement is in the Settlement Class members' best interest and provides them with a substantial benefit now, instead of engaging in years of further uncertain and expensive litigation; likely discovery disputes; a contested motion for class certification; the Parties' competing motions for summary judgment; pre-trial evidentiary motions; and a lengthy trial; likely appeals; and attempts to enforce any judgment — much of which could result in the Settlement Class receiving no recovery at all. By settling the Action with the Defendants at this point, Lead Plaintiff is not admitting that the Action lacked merit, or that the Settlement Class's ultimate recovery would not have been greater than the Settlement Amount had litigation continued. Neither the Stipulation, nor any of its terms or provisions, nor any of the negotiations or proceedings connected with it, shall be construed as an admission or concession by the Lead Plaintiff or the Settlement Class members that any of their claims lack merit; that any defenses asserted by any of the Defendants in the Action have any merit; or that damages recoverable in the Action would not have exceeded the Settlement Amount.

Defendants have denied, and continue to deny, that they engaged in any wrongdoing of any kind, or that they violated or breached any law, regulation, or duty owed to Lead Plaintiff or the other Settlement Class members, or that they have liability as a result of the allegations made and claims brought by Lead Plaintiff. Defendants maintain that they have meritorious defenses and believe they would have prevailed at any trial in this Action. Nonetheless, Defendants have concluded that further litigation of this Action would be protracted and expensive, taking into account the uncertainty and risks inherent in any litigation, especially in complex cases like this Action. Defendants have, therefore, determined that it is desirable and beneficial to fully and finally settle the Released Claims on the terms set forth in the Stipulation.

The Settlement must be compared to the risk of no recovery after contested dispositive motions, trial, and likely appeals. A trial is a risky proposition. The claims in the Action involve numerous complex legal and factual issues, many of which would require expert testimony. The Parties disagree on both liability and damages, and do not agree on the average amount of damages per share, if any, that would be recoverable if Lead Plaintiff were to prevail on each claim alleged against the Defendants. Among their many other disagreements are: (1) whether the Defendants violated the securities laws or otherwise engaged in wrongdoing; (2) whether the misrepresentations and omissions alleged by Lead Plaintiff were material, false, misleading or otherwise actionable; (3) the extent (if any) that the alleged misrepresentations and omissions influenced ImmunityBio's stock price during the Settlement Class Period; and (4) the method for determining whether, and the extent to which, purchasers of ImmunityBio stock suffered injury and damages that could be recovered at trial.

## WHO IS IN THE SETTLEMENT

To see if you will get money from this Settlement, you first have to decide if you are a Settlement Class member.

### 5. How do I know if I am part of the Settlement?

The Settlement Class includes all persons who purchased or acquired ImmunityBio (NASDAQ: IBRX) securities between March 10, 2021, and May 10, 2023, both dates inclusive, except for those expressly excluded from the Settlement Class as detailed in the following section.

### 6. Are there exceptions to being included?

Yes. You are not a member of the Settlement Class if you did not purchase or acquire ImmunityBio securities on or between the dates listed above. If you purchased or acquired ImmunityBio securities some other time, or did not purchase or acquire it at all, you are not included within the Settlement Class.

You are also not a member of the Settlement Class if you are on the list of persons and entities that are specifically excluded from it, per question 3 above.

### 7. What if I am still not sure if I am included?

If you are still not sure whether you are included, you can ask for free help. You can contact the Claims Administrator toll-free at 1-888-853-4782 or at [ImmunityBioSecuritiesSettlement.com](http://ImmunityBioSecuritiesSettlement.com) for more information. Or you can fill out and return the Proof of Claim Form enclosed with this No-tice package, with appropriate supporting documentation, to see if you qualify.

## THE SETTLEMENT BENEFITS – WHAT YOU GET

### 8. What does the Settlement provide?

In exchange for the Settlement and release of the Lead Plaintiff's Claims (defined below) as well as dismissal of the Action, Defendants have agreed to pay, or cause to be paid, ten million five hundred thousand dollars (\$10,500,000.00) to be divided, after payment of Court-approved attorneys' fees and expenses, the costs of claims administration, including the costs of printing and mailing this Notice and the cost of publishing notice, any compensatory award granted to Lead Plaintiff, and Taxes and Tax Expenses (the "Net Settlement Fund"), *pro rata* among all Settlement Class members who send in a valid Proof of Claim Form.

### 9. How much will my payment be?

Your share of the Net Settlement Fund will depend on several factors, including the following: how many Settlement Class members submit timely and valid Proof of Claim Forms; the total Recognized Losses represented by the valid Proof of Claim Forms that the Settlement Class members send in; your Recognized Losses, based on the number of ImmunityBio shares you purchased during the Settlement Class Period, how much you paid for them, when you purchased them, and, if you sold them, when, and for how much, you sold them.

By following the instructions in the Plan of Allocation, you can calculate what is called your Recognized Loss. It is unlikely that you will get a payment for all of your Recognized Loss. After all Settlement Class members have sent in their Proof of Claim Forms, the payment you get will be a part of the Net Settlement Fund equal to your Recognized Loss divided by the total of everyone's Recognized Losses. See the Plan of Allocation below for more information.

## HOW YOU GET A PAYMENT — SUBMITTING A CLAIM FORM

### 10. How can I get a payment?

To qualify for a payment, you must submit a Proof of Claim Form, maybe downloaded at [www.ImmunityBioSecuritiesSettlement.com](http://www.ImmunityBioSecuritiesSettlement.com). Read the instructions carefully, fill out the Form completely, include all the documents that the Form asks for, sign it, and mail or submit it online so that it is received no later than July 7, 2025.

### 11. When would I get my payment?

The Court will hold a Settlement Fairness Hearing on June 13, 2025, at 1:30 pm. to decide whether to approve the Settlement. If the Court approves the Settlement, there might be appeals afterwards. It is always uncertain whether these appeals can be resolved, and resolving them can take time, perhaps more than a year. It also takes time for all the Proof of Claim Forms to be processed, including the process of identifying and attempting to cure defects in Proof of Claim Forms that were submitted by Settlement Class members. Please be patient.

### 12. What am I giving up to get a payment or to stay in the Class?

Unless you timely exclude yourself from the Settlement Class, you will remain a Settlement Class member and will be bound by the Releases set forth in the Stipulation. That means you cannot sue, continue to sue, or be part of any other lawsuit against the Defendants or the other Released Defendant Parties about Lead Plaintiff's Claims in this Action. It also means that all of the Court's orders will apply to you and legally bind you, and you will release your claims in this Action against the Defendants and the other Released Defendants' Parties. The Stipulation excludes from the definition of Lead Plaintiff's Claims derivative claims asserted by shareholders on behalf of ImmunityBio in a related matter captioned *Van Luven v. Soon-Shiong, et al.*, No. 24-cv-2-14 (S.D. Cal.). After the Parties entered the Stipulation, two additional shareholder derivative actions were filed, *Barbieri v. Soon-Shiong, et al.*, No. 25-cv-416 (S.D. Cal.) and *Shin v. Soon-Shion, et al.*, No. 25-cv-423 (S.D. Cal.), which make substantially similar allegations as those alleged in *Van Luven*. The terms of the Releases are included in the Proof of Claim Form that is found on the Settlement website at [www.ImmunityBioSecuritiesSettlement.com](http://www.ImmunityBioSecuritiesSettlement.com).



## EXCLUDING YOURSELF FROM THE SETTLEMENT

If you do not want a payment from this Settlement, and you want to keep the right to sue the Defendants and the other Released Defendant Parties on your own about the legal issues that were litigated in this Action, then you must take steps to remove yourself from the Settlement Class. This is called excluding yourself from — sometimes referred to as “opting out” — of the Settlement Class. If you decide to exclude yourself from the Settlement Class, and wish to file your own individual lawsuit, Defendants may argue in the future that you face a time bar under applicable statutes of limitation or repose, risks that you should discuss with an appropriate legal advisor.

### 13. How do I get out of the proposed Settlement?

To exclude yourself from the Settlement Class, you must send a letter by First-Class Mail (email or phone call will not suffice) stating that you “request exclusion from the Settlement Class in *In re ImmunityBio, Inc. Securities Litigation*, Case No. 3:23-cv-01216-GPC-VET.” Your letter must include the date(s), price(s), and number(s) of all purchases and sales of ImmunityBio securities during the Settlement Class Period. In addition, you must include your name, address, telephone number, and your signature. You must mail your exclusion no later than May 23, 2025, to:

ImmunityBio Securities Settlement  
c/o Epiq  
PO Box 2239  
Portland, OR 97208-2239

**If you ask to be excluded, you will not get any payment, and you cannot object to the Settlement. You will not be legally bound by anything that happens in the Action.**

### 14. If I do not exclude myself, can I sue the Defendants and the other Released Defendant Parties for the same thing later?

No. Unless you exclude yourself from the Settlement Class, you give up any rights to sue the Defendants and the other Released Defendant Parties in connection with Lead Plaintiff’s Claims. The meaning of Lead Plaintiff’s Claims and claims that are excluded are included in the Proof of Claim Form that is enclosed, as well as in the Stipulation that is posted on the Claims Administrator’s Settlement website. If you have a pending lawsuit against the Defendants or other Released Defendant Parties based on the Released Lead Plaintiff Parties’ Claims, speak to your lawyer in that case immediately. You must exclude yourself from this Action to continue your own lawsuit. Remember, the exclusion deadline is May 23, 2025.

### 15. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself, you may not send in a Proof of Claim Form to ask for any money from this Settlement.

## THE LAWYERS REPRESENTING YOU

### 16. Do I have a lawyer in this case?

The Court ordered that the law firms of Pomerantz LLP and Holzer & Holzer, LLC shall represent the Settlement Class members, including you. These lawyers are referred to as Co-Lead Counsel. You will not be personally liable for the fees and expenses incurred by these lawyers, which will be paid from the Settlement Fund, as approved by the Court. If you want to be represented by your own lawyer, you may hire one at your own expense.

### 17. How will the lawyers be paid?

Co-Lead Counsel have litigated this Action since June 2023 on a wholly contingent basis, meaning that they have not been paid any attorneys’ fees for the time devoted to the lawsuit, nor have they been reimbursed for their out-of-pocket expenses incurred in connection with litigating the Action during that time period. As such, as part of the Settlement approval process, Co-Lead Counsel will move the Court for an award of attorneys’ fees in an amount not to exceed one third (33 and ⅓%) of the Settlement Fund and for out-of-pocket expenses in an amount not to exceed two hundred thousand (\$200,000) in connection with the litigation, plus interest earned on such fees and expenses. The Court will decide whether to grant this request, and, if it is granted, how much to award Co-Lead Counsel. Such sums as may be approved by the Court will be paid from the Settlement Fund.

Co-Lead Counsel will file one or more formal motions with the Court for approval of the Settlement, the Plan of Allocation, the request for attorneys' fees and reimbursement of expenses, and the request for a compensatory award to Lead Plaintiff no later than May 14, 2025.

Co-Lead Counsel believes that the requested attorneys' fees are warranted in light of their efforts, on a wholly contingent basis, to investigate the underlying claims, to work with a private investigator and a damages consultant, to file an initial Complaint, to file a First Amended Class Action Complaint after continued investigation and their appointment as Co-Lead Counsel, to litigate and overcome Defendants' motion to dismiss, to secure key discovery from Defendants and respond to discovery requests from Defendants, to prepare a detailed mediation statement, to mediate the dispute for a full day before an experienced mediator and thereafter to negotiate the Settlement and work to memorialize it in a Confidential Term Sheet and then a detailed Stipulation with a proposed proof of claim form and proposed notices, and submit the Settlement to the Court for necessary approvals. Co-Lead Counsel's motion will argue that the requested fees are well within the range of fees awarded to class counsel under similar circumstances in other cases of this type and are reasonable when compared against Co-Lead Counsel's actual time devoted to the litigation of the Action at the applicable billing rates of Co-Lead Counsel's attorneys and paralegals. The Court determines what to award Co-Lead Counsel as fees and expenses from the Settlement Fund and may award more or less than the amount requested, in its discretion.

### OBJECTING TO THE SETTLEMENT

#### 18. How do I tell the Court that I object to the proposed Settlement?

If you are a Settlement Class member, you can object to the proposed Settlement, the proposed Plan of Allocation, any proposed compensatory award to Lead Plaintiff, and/or Co-Lead Counsel's fee, cost, and expense application. You can write to the Court setting out your objection. The Court will consider your views. To object, you must send a signed letter saying that you object to the proposed Settlement in *In re ImmunityBio, Inc. Securities Litigation*, Case No. 3:23-cv-01216-GPC-VET (S.D. Cal.). Be sure to include your name, address, telephone number, and your signature, identify the date(s), price(s), and number(s) of ImmunityBio securities that you purchased or otherwise acquired and sold or otherwise disposed of during the Settlement Class Period, and state the reasons why you object to the proposed Settlement. If you object to either the Settlement, requested attorneys' fees or reimbursement of expenses, or Lead Plaintiff's compensatory award, you subject yourself to the jurisdiction of the Court in this matter, and Lead Plaintiff, acting through Co-Lead Counsel, will have the right to take your deposition prior to the Settlement Fairness Hearing. If you refuse to have your deposition testimony taken upon Lead Plaintiff's request, your objection will be deemed invalid. Your objection must be filed with the Court **and** mailed or delivered to **each** of the following addresses by no later than May 23, 2025.

COURT	CO-LEAD COUNSEL	DEFENDANTS' COUNSEL
Clerk of the Court United States District Court Southern District of California James M. Carter and Judith N. Keep United States Courthouse 333 West Broadway San Diego, CA 92101	Jeremy Lieberman <b>POMERANTZ LLP</b> 600 Third Avenue 20 <sup>th</sup> Floor New York, NY 10016  Corey D. Holzer Marshall Dees <b>HOLZER &amp; HOLZER, LLC</b> 211 Perimeter Center Parkway, Suite 1010 Atlanta, GA 30346	Gregory Watts <b>Wilson Sonsini Goodrich &amp; Rosati, P.C.</b> 701 5th Ave. Suite 5100 Seattle, WA 98104

#### 19. What is the difference between objecting and excluding myself?

Objecting is simply telling the Court that you do not like something about the proposed Settlement. You can object only if you stay in the Settlement Class. Excluding yourself is telling the Court that you do not want to be part of the Settlement Class and do not want to seek a payment from the Settlement Fund. If you exclude yourself, you have no basis to object because the case no longer affects you.

## THE COURT'S SETTLEMENT HEARING

The Court will hold a hearing to decide whether to approve the proposed Settlement. You may attend, and you may ask to speak, but you do not have to do so.

### **20. When and where will the Court decide whether to approve the proposed Settlement?**

The Court will hold a Settlement Fairness Hearing on June 13, 2025, at 1:30 pm., at the Edward J. Schwartz United States Courthouse, 221 West Broadway, San Diego, CA 92101, in Courtroom 2D, for the following reasons: to determine whether the proposed Settlement of the Action on the terms and conditions provided for in the Stipulation is fair, reasonable, and adequate to the Settlement Class and should be approved by the Court; to determine whether a proposed Order and Final Judgment as provided in the Stipulation should be entered; to determine whether the proposed Plan of Allocation for distributing Settlement proceeds to Settlement Class members should be approved; to determine the amount of fees, costs, and expenses that should be awarded to Co-Lead Counsel; to determine the amount of any compensatory award to Lead Plaintiff for his service to the Settlement Class; and to consider such other matters as the Court may deem appropriate. If there are objections, the Court will consider them. The Court will listen to people who have asked to speak at the Settlement Fairness Hearing.

At or after the Settlement Fairness Hearing, the Court will decide whether to approve the Settlement and whether to grant, and, if so, the amount, of any awards to Co-Lead Counsel and to Lead Plaintiff. We do not know how long these decisions will take.

You should be aware that the Court may change the date and time of the Settlement Hearing without another notice being sent to Settlement Class members, though any revised dates or times will be promptly posted to the Claims Administrator's Settlement website. The Court may also choose to hold the Settlement Hearing additionally or exclusively by teleconference or over the Court's virtual (Zoom) service.

### **21. Do I have to come to the hearing?**

No. Co-Lead Counsel will answer questions the Court may have and has extensive experience handling settlement-related hearings of this nature. But you are welcome to come at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mailed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but it is not necessary. Settlement Class members do not need to appear at the hearing or take any other action to indicate their approval.

### **22. May I speak at the hearing?**

If you object to the Settlement, you may ask the Court for permission to speak at the Settlement Hearing. To do so, you must include with your objection (see question 18 above) a statement saying that it is your "intention to appear in *In re ImmunityBio, Inc. Securities Litigation*, Case No. 3:23-cv-01216-GPC-VET." Persons who intend to object to the Settlement, the Plan of Allocation, any proposed compensatory award, and/or the application for an award of attorneys' fees, costs, and expenses and desire to present evidence at the Settlement Hearing must include in their written objections the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the Settlement Hearing. You cannot speak at the hearing if you exclude yourself.

## IF YOU DO NOTHING

### **23. What happens if I do nothing at all?**

If you do nothing, all of your claims against the Defendants and the other Released Defendant Parties will be released, but you will not receive any money from this Settlement, because it is necessary to submit a Proof of Claim Form, with appropriate supporting documentation, to share in the Settlement proceeds.



## GETTING MORE INFORMATION

### 24. Are there more details about the proposed Settlement?

This Notice summarizes the proposed Settlement. More details are in the Stipulation. The Stipulation is the controlling document describing the proposed Settlement and its terms govern anything to the contrary in this Notice. You can get a copy of the Stipulation and obtain answers to common questions regarding the proposed Settlement by contacting the Claims Administrator toll-free at 1-888-853-4782 or by downloading it from the Claims Administrator's Settlement website at [www.ImmunityBioSecuritiesSettlement.com](http://www.ImmunityBioSecuritiesSettlement.com).

### 25. How do I get more information?

For even more detailed information concerning the matters involved in this Action, reference is made to the Stipulation, to the filings in support of the Settlement, to the Orders entered by the Court, and to the other Settlement-related papers filed in the Action, which will be posted on the settlement website at [www.ImmunityBioSecuritiesSettlement.com](http://www.ImmunityBioSecuritiesSettlement.com).

#### PLAN OF ALLOCATION OF NET SETTLEMENT FUND AMONG SETTLEMENT CLASS MEMBERS

The objective of the Plan of Allocation is to equitably distribute the Net Settlement Fund among Authorized Claimants based on their respective alleged economic losses as a result of the alleged fraud, as opposed to losses caused by market- or industry-wide factors, or company-specific factors unrelated to the alleged fraud. The Claims Administrator shall determine each Authorized Claimant's share of the Net Settlement Fund based upon the recognized loss formula (the "Recognized Loss") described below.

A Recognized Loss will be calculated for each share of ImmunityBio common stock purchased or acquired during the Settlement Class Period. The calculation of Recognized Loss will depend upon several factors, including when shares of ImmunityBio common stock were purchased or acquired during the Settlement Class Period, and in what amounts, and whether those shares were sold, and if sold, when they were sold, and for what amounts. The Recognized Loss is not intended to estimate the amount a Settlement Class member might have been able to recover after a trial, nor to estimate the amount that will be paid to Authorized Claimants pursuant to the Settlement. The Recognized Loss is the basis upon which the Net Settlement Fund will be proportionately allocated to the Authorized Claimants. The Claims Administrator will use its best efforts to administer and distribute the Net Settlement Fund to the extent that it is equitably and economically feasible.

The Plan of Allocation was created with the assistance of a consulting damages expert and reflects the assumption that the prices of ImmunityBio securities were artificially inflated throughout the Settlement Class Period. The estimated alleged artificial inflation in the prices of ImmunityBio stock during the Settlement Class Period is reflected in Table 1 below. The computation of the estimated alleged artificial inflation in the prices of ImmunityBio stock during the Settlement Class Period is based on certain misrepresentations alleged by Lead Plaintiff and the price change in the stock, net of market and industry-wide factors, in reaction to the public announcements that allegedly corrected the misrepresentations alleged by Lead Plaintiff. As reflected in Table 1, the first such alleged misrepresentation was made on March 10, 2021, thus there was no price inflation in ImmunityBio stock on March 9, 2021 or earlier. Moreover, the last alleged corrective disclosure or event occurred on May 11, 2023, thus all alleged price inflation is alleged to have been removed from ImmunityBio's stock that day.

The U.S. federal securities laws allow investors to recover for losses caused by disclosures which corrected a defendants' previous misleading statements or omissions. Thus, in order to have been damaged by the alleged violations of the federal securities laws, ImmunityBio common stock purchased or acquired during the Settlement Class Period must have been held during a period of time in which its price declined due to the disclosure of information which corrected a misleading statement or omission allegedly made by Defendants. Lead Plaintiff and Co-Lead Counsel have determined that such a price decline occurred on May 11, 2023 (the "Corrective Disclosure Date"). Accordingly, if a share ImmunityBio common stock was sold before May 11, 2023 (i.e., the Corrective Disclosure Date), the Recognized Loss for that share is \$0.00, and any loss suffered is not compensable under the federal securities laws.

**Table 1:  
Artificial Inflation in ImmunityBio Stock<sup>1</sup>**

<b>From</b>	<b>To</b>	<b>Per-Share Price Inflation</b>
March 10, 2021	May 10, 2023	\$3.38
May 11, 2023	Thereafter	\$0.00

The “90-day look back” provision of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) is incorporated into the calculation of the Recognized Loss for ImmunityBio stock. The limitations on the calculation of the Recognized Loss imposed by the PSLRA are applied such that losses on ImmunityBio stock purchased during the Settlement Class Period and held as of the close of the 90-day period subsequent to the Settlement Class Period (the “90-Day Lookback Period”) cannot exceed the difference between the purchase price paid for such stock and its average price during the 90-Day Lookback Period. The Recognized Loss on ImmunityBio stock purchased during the Settlement Class Period and sold during the 90-Day Lookback Period cannot exceed the difference between the purchase price paid for such stock and its rolling average price during the portion of the 90-Day Lookback Period elapsed as of the date of sale.

In the calculations below, all purchase and sale prices shall exclude any fees, taxes and commissions. If a Recognized Loss amount is calculated to be a negative number, that Recognized Loss shall be set to zero.

### **Calculation of Recognized Loss Per Share of ImmunityBio Stock**

The Recognized Loss for each share of ImmunityBio common stock that was purchased or acquired during the Settlement Class Period (*i.e.*, between March 10, 2021, and May 10, 2023, both dates inclusive) shall be calculated as follows:

- i. For each share of ImmunityBio stock purchased during the Settlement Class Period that was subsequently sold prior to May 11, 2023, the Recognized Loss per share is \$0.
- ii. For each share of ImmunityBio stock purchased during the Settlement Class Period that was subsequently sold during the period May 11, 2023, through August 8, 2023, inclusive (*i.e.*, the 90-Day Lookback Period), the Recognized Loss per share is the *lesser* of:
  - a. the amount of per-share price inflation on the date of purchase as appears in Table 1 above; or
  - b. the purchase price *minus* the “90-Day Lookback Value” on the date of sale provided in Table 2 below.
- iii. For each share of ImmunityBio stock purchased during the Settlement Class Period and still held as of the close of trading on August 8, 2023, the Recognized Loss per share is the *lesser* of:
  - a. the amount of per-share price inflation on the date of purchase as appears in Table 1 above; or
  - b. the purchase price *minus* the average closing price for Immunity Bio stock during the 90-Day Lookback Period, which is \$2.68.

**TABLE 2: AVERAGE CLOSING PRICE OF IMMUNITYBIO COMMON STOCK (90-DAY LOOK-BACK)**

<b>Sale / Disposition Date</b>	<b>90-Day Lookback Value</b>	<b>Sale / Disposition Date</b>	<b>90-Day Lookback Value</b>	<b>Sale / Disposition Date</b>	<b>90-Day Lookback Value</b>
May 11, 2023	\$2.79	June 12, 2023	\$2.84	July 13, 2023	\$2.78
May 12, 2023	\$2.54	June 13, 2023	\$2.84	July 14, 2023	\$2.78
May 15, 2023	\$2.76	June 14, 2023	\$2.84	July 17, 2023	\$2.79
May 16, 2023	\$2.90	June 15, 2023	\$2.84	July 18, 2023	\$2.79
May 17, 2023	\$2.97	June 16, 2023	\$2.84	July 19, 2023	\$2.80
May 18, 2023	\$2.94	June 20, 2023	\$2.84	July 20, 2023	\$2.80
May 19, 2023	\$2.94	June 21, 2023	\$2.84	July 21, 2023	\$2.80
May 22, 2023	\$2.93	June 22, 2023	\$2.84	July 24, 2023	\$2.80

<sup>1</sup> Any transactions in ImmunityBio stock executed outside of regular trading hours for the U.S. financial markets shall be deemed to have occurred during the next regular trading session.

## EXHIBIT B-1

May 23, 2023	\$2.91	June 23, 2023	\$2.83	July 25, 2023	\$2.80
May 24, 2023	\$2.88	June 26, 2023	\$2.83	July 26, 2023	\$2.79
May 25, 2023	\$2.83	June 27, 2023	\$2.82	July 27, 2023	\$2.78
May 26, 2023	\$2.81	June 28, 2023	\$2.81	July 28, 2023	\$2.77
May 30, 2023	\$2.78	June 29, 2023	\$2.81	July 31, 2023	\$2.76
May 31, 2023	\$2.78	June 30, 2023	\$2.81	August 1, 2023	\$2.75
June 1, 2023	\$2.79	July 3, 2023	\$2.81	August 2, 2023	\$2.73
June 2, 2023	\$2.79	July 5, 2023	\$2.81	August 3, 2023	\$2.72
June 5, 2023	\$2.79	July 6, 2023	\$2.80	August 4, 2023	\$2.71
June 6, 2023	\$2.82	July 7, 2023	\$2.80	August 7, 2023	\$2.70
June 7, 2023	\$2.83	July 10, 2023	\$2.80	August 8, 2023	\$2.68
June 8, 2023	\$2.84	July 11, 2023	\$2.79		
June 9, 2023	\$2.84	July 12, 2023	\$2.79		

### INSTRUCTIONS APPLICABLE TO ALL CLAIMANTS

The payment you receive will reflect your proportionate share of the Net Settlement Fund. Such payment will depend on the number of eligible shares that participate in the Settlement, which is determined based on the number of Proof of Claim Forms submitted and accepted as valid, and when those shares were purchased and sold. The number of claimants who send in claims varies widely from case to case.

A purchase or sale of ImmunityBio stock shall be deemed to have occurred on the “contract” or “trade” date as opposed to the “settlement” or “payment” date.

All purchase and sale prices shall exclude any fees and commissions.

If a Settlement Class member acquired ImmunityBio stock during the Settlement Class Period by way of gift, inheritance or operation of law, such a claim will be computed by using the date and price of the original purchase and not the date and price of transfer. To the extent that ImmunityBio shares were originally purchased prior to commencement of the Settlement Class Period, the Recognized Loss for that acquisition shall be deemed to be zero (\$0.00).

Notwithstanding any of the above, receipt of ImmunityBio stock during the Settlement Class Period in exchange for securities of any other corporation or entity shall not be deemed a purchase or sale of ImmunityBio stock.

In the event a Settlement Class member has more than one acquisition or sale of ImmunityBio securities, the first-in-first-out (“FIFO”) basis will be applied to such purchases and sales. Sales will be matched in chronological order, by trade date, first against ImmunityBio stock held as of the close of trading on March 9, 2021 (the last day before the Settlement Class Period begins) and then against the purchase of ImmunityBio stock during the Settlement Class Period.

The date of covering a “short sale” is deemed to be the date of purchase of shares. The date of a “short sale” is deemed to be the date of sale of shares. In accordance with the Plan of Allocation, however, the Recognized Loss on “short sales” is zero. In the event that a claimant has an opening short position in ImmunityBio stock, the earliest Settlement Class Period purchases shall be matched against such opening short position and not be entitled to a recovery until that short position is fully covered.

With respect to ImmunityBio stock purchased or sold through the exercise of an option, the purchase/sale date of the stock shall be the exercise date of the option, and the purchase/sale price of the stock shall be the closing price of ImmunityBio stock on the date of exercise. Any Recognized Loss arising from purchases of ImmunityBio stock acquired during the Settlement Class Period through the exercise of an option on ImmunityBio stock<sup>2</sup> shall be computed as provided for other purchases of ImmunityBio stock in the Plan of Allocation.

<sup>2</sup> The “exercise of an option” as used in this sentence includes: (1) purchases of ImmunityBio stock as the result of the exercise of a call option, and (2) purchases of ImmunityBio stock by the seller of a put option as a result of the buyer of such put option exercising that put option.

## EXHIBIT B-1

Payment according to the Plan of Allocation will be deemed conclusive against all Authorized Claimants. A Recognized Loss will be calculated as defined herein and cannot be less than zero. The Claims Administrator shall allocate to each Authorized Claimant a *pro rata* share of the Net Settlement Fund based on his, her, or its Recognized Loss as compared to the total Recognized Losses of all Authorized Claimants. No distribution will be made to Authorized Claimants who would otherwise receive a distribution of less than \$10.00.

Settlement Class members who do not submit an acceptable Proof of Claim Form, with appropriate supporting documentation, will not share in the Settlement proceeds. The Settlement and the proposed Final Order and Judgment dismissing this Action with prejudice will nevertheless bind Settlement Class members who do not submit a request for exclusion and/or submit an acceptable Proof of Claim Form.

Please contact the Claims Administrator or Co-Lead Counsel if you disagree with any determinations made by the Claims Administrator regarding your Proof of Claim Form. If you are unsatisfied with the determinations, you may ask the Court, which retains jurisdiction over all Class members and the claims-administration process, to decide the issue by submitting a written request.

Defendants, their respective counsel, and all other Released Defendant Parties will have no responsibility or liability whatsoever for the processing of Proof of Claim Forms, the investment of the Settlement Fund, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. Lead Plaintiff and Co-Lead Counsel, likewise, will have no liability for their reasonable efforts to execute, administer, and distribute the Settlement.

Distributions will be made to Authorized Claimants after all claims have been processed and after the Court has finally approved the Settlement. If any funds remain in the Net Settlement Fund by reason of uncashed distribution checks or otherwise, then, after the Claims Administrator has made reasonable and diligent efforts to have Class members who are entitled to participate in the distribution of the Net Settlement Fund cash their distributions, any balance remaining in the Net Settlement Fund after at least six (6) months after the initial distribution of such funds will be used in the following fashion: (a) first, to pay any amounts mistakenly omitted from the initial disbursement; (b) second, to pay any additional settlement administration fees, costs, and expenses, including those of Co-Lead Counsel or the Claims Administrator as may be approved by the Court; and (c) finally, to make a second distribution to claimants who cashed their checks from the initial distribution and who would receive at least \$10.00, after payment of the estimated costs, expenses, or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. These redistributions shall be repeated, if economically feasible, until the balance remaining in the Net Settlement Fund is *de minimis* and such remaining balance will then be distributed pursuant to a method approved by the Court.

### **SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES**

If you purchased ImmunityBio securities during the Settlement Class Period, including ImmunityBio common stock (CUSIP: 45256X103) (NASDAQ: IBRX), for the beneficial interest of an individual or organization other than yourself, the Court has directed that, WITHIN TEN (10) DAYS OF YOUR RECEIPT OF THIS NOTICE, you either (a) provide to the Claims Administrator the name and last known address of each person or organization for whom or which you purchased such common shares during such time period, or (b) request additional copies of this Notice and the Proof of Claim Form, which will be provided to you free of charge, and within ten (10) days of receipt mail them directly to the beneficial owners of the common stock referred to herein. If you choose to follow alternative procedure (b), upon such mailing, you must send a statement to the Claims Administrator confirming that the mailing was made as directed and retain the names and addresses of the addressees for any future mailings to Settlement Class members. You are entitled to reimbursement from the Settlement Fund of your reasonable expenses actually incurred in connection with the foregoing, up to \$0.73 per notice mailed or \$0.15 per name and address provided to Claims Administrator, which expenses would not have been incurred except for the sending of such notice, and subject to further order of the Court with respect to any dispute concerning such reimbursement. These expenses will be paid upon request and submission of appropriate supporting documentation. All communications concerning the foregoing should be addressed to the Claims Administrator at:

ImmunityBio Securities Settlement  
c/o Epiq  
PO Box 2239  
Portland, OR 97208-2239

Dated: April 7, 2025

BY ORDER OF THE COURT  
UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF CALIFORNIA